ArticleInfection and immunity2005
Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis.
Article in Infection and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 1 synthesis or guideline pooled it, 228 citations in OpenAlex.
- A meta-analysis-informed diagnostic stratification tool for invasive pulmonary aspergillosis in severe fever with thrombocytopenia syndrome: systematic review, meta-analysis, and single-center cohort-based assessment.Frontiers in cellular and infection microbiology · 2026Pooled it
- Pulmonary fibroblast activation during Aspergillus fumigatus infection enhances lung defense via immunomodulation and tissue remodeling.Nature communications · 2026Article
- Invasive pulmonary aspergillosis in the ICU: the corticosteroid link.Pneumonia (Nathan Qld.) · 2026Review
- Development and Internal Validation of a Nomogram Model to Predict Invasive Pulmonary Aspergillosis Occurrence Risk in ICU Patients with Sepsis.Infection and drug resistance · 2026Article
- Establishment and validation of a predictive nomogram for voriconazole-associated liver injury in lung transplant patients.International journal of clinical pharmacy · 2025Observational
- Emerging Risk Factors for Invasive Pulmonary Aspergillosis: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Improved Methodology for Liquid Delivery to the Mouse Lung: Intubation using a Consumer Otoscope.Journal of visualized experiments : JoVE · 2025Article
- Preclinical Models for Cryptococcosis of the CNS and Their Characterization Using In Vivo Imaging Techniques.Journal of fungi (Basel, Switzerland) · 2024Review
- Role of theJournal of fungi (Basel, Switzerland) · 2024Article
- Experimental Models to Study the Pathogenesis and Treatment of Mucormycosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Improved diagnostic markers for invasive pulmonary aspergillosis in COPD patients.Frontiers in cellular and infection microbiology · 2024Article
- Article
- A Pathology-based Case Series of Influenza- and COVID-19-associated Pulmonary Aspergillosis: The Proof Is in the Tissue.American journal of respiratory and critical care medicine · 2023Article
- Mouse Models of Mucormycosis.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Article
- Neutrophil and Macrophage NADPH Oxidase 2 Differentially Control Responses to Inflammation and to Aspergillus fumigatus in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- The Changing Landscape of Invasive Fungal Infections in ICUs: A Need for Risk Stratification to Better Target Antifungal Drugs and the Threat of Resistance.Journal of fungi (Basel, Switzerland) · 2022Review
- Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis.Microbiology spectrum · 2022Article
- Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets.Diagnostics (Basel, Switzerland) · 2022Review
- Therapeutic effects of pentoxifylline on invasive pulmonary aspergillosis in immunosuppressed mice.BMC pulmonary medicine · 2021Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus fumigatus causes invasive pulmonary aspergillosis (IPA). This disease is one of the most life-threatening opportunistic infections in immunocompromised patients. The type of immunosuppressive regimen under which IPA occurs has rarely been investigated. In this study, we evaluated various parameters of the innate immune response during the progression of murine IPA induced by the intratracheal administration of A. fumigatus conidia as a function of two immunosuppressive treatments: a corticosteroid and a chemotherapeutic agent. We compared host responses various times after infection in terms of survival, pulmonary production of pro- and anti-inflammatory cytokines, cellular trafficking in the airways, lung injury, respiratory distress, and fungal development. We found that IPA pathogenesis involved predominantly fungal development in mice treated by chemotherapy and an adverse host response in mice treated with a corticosteroid. These previously unrecognized differences should be taken into account in evaluations of the pathogenesis of IPA in animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.